Agenus

Agenus, Inc. is a clinical-stage immuno-oncology company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava in March 31, 1994 and is headquartered in Lexington, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Agenus reports robust Q4 earnings, advances immuno-oncology pipeline

Agenus showcased strong financials, progress in immuno-oncology pipeline, and durable responses in various cancers
Strategic partnerships and innovative R&D capabilities position the company well for future growth and development
Challenges in enrollment, differentiation, and managing immune-related toxicities are being actively addressed for continued success

Agenus (AGEN) reports progress in cancer treatment programs

Agenus (AGEN) showcased strong progress in its cancer treatment programs, with notable response rates and Fast Track Designation for a promising combination therapy.
While financials remained stable, the company faces challenges in maintaining response rates and successful study enrollments, requiring effective regulatory navigation and communication strategies.
Opportunities for Agenus include presenting at ASCO, expanding development programs, and attracting partnerships to drive further advancements in oncology treatments.

Agenus reports positive trial outcomes and strong regulatory strategy

Agenus is making significant progress in cancer treatment with positive trial outcomes and a strong regulatory strategy.
The company's commitment to innovation, patient quality of life, and managing side effects positions them well for future success.
Challenges include addressing analyst inquiries, enrollment in studies, and managing toxicities, but opportunities exist in partnerships and targeted treatment approaches.

Agenus reports robust earnings, eyes strategic partnerships for growth

Agenus Inc. demonstrated strong financial performance and progress in its BOT/BAL program.
While facing challenges in trial enrollment and funding, the company is focused on strategic partnerships.
Opportunities lie in upcoming data disclosures, potential BLA submissions, and product launches.

Agenus reports Q1 2024 financials, progresses BOT/BAL program for growth

Agenus navigates financial challenges with a focus on advancing the BOT/BAL program towards commercialization. Despite losses, the company's strategic initiatives position it for potential growth opportunities through milestone achievements and market expansion.

Agenus (AGEN) reports Q3 loss, advances cancer therapy innovations

Agenus (AGEN) is navigating financial challenges with a focus on advancing transformative cancer therapy and strategic partnerships.
Despite a net loss of $67 million, progress in BOT/BAL development and strategic initiatives position Agenus for future growth.
Opportunities in upcoming clinical studies and data readouts in 2025 underscore the company's commitment to innovation and patient care.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Agenus, Inc. is a clinical-stage company, which engages in the development and commercialization of technologies to treat cancers and infectious diseases. Its product pipeline includes Balstilimab, Zalifrelimab, AGEN1181, AGEN1327, AGEN2373, AGENt-797 and AGEN1777. The company was founded by Garo H. Armen and Pramod K. Srivastava on March 31, 1994 and is headquartered in Lexington, MA.

LOS ANGELES, CA / ACCESSWIRE / September 15, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 23, 2023 and July 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 5, 2024.

The Schall Law Firm Seeks Investor Participation In A Case Against Agenus Inc. For Securities Law Violations

LOS ANGELES, CA / ACCESSWIRE / September 14, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 23, 2023 and July 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 5, 2024.

Agenus Inc Is Being Sued For Possible Securities Fraud And Stockholders With Losses Are Urged To Contact The Schall Law Firm

NEW YORK, NY / ACCESSWIRE / September 13, 2024 / If you suffered a loss on your Agenus Inc. (NASDAQ:AGEN) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/agenus-lawsuit-submission-form?prid=102546&wire=1 or contact Joseph E. Levi, Esq.

Investors who lost money on Agenus Inc. (AGEN) should contact Levi & Korsinsky about pending Class Action - AGEN

LOS ANGELES, CA / ACCESSWIRE / September 13, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 23, 2023 and July 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 5, 2024.

The Schall Law Firm Seeks Shareholder Participation In A Case Against Agenus Inc. For Securities Law Violations

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, presented data today at the European Society for Medical Oncology (ESMO) Congress held in Barcelona, Spain. The data from a Phase 1 study of botensilimab (BOT), an investigational Fc-enhanced CTLA-4 inhibitor, in combination with balstilimab (BAL), an investigational PD-1 antibody, showed clinical activity in patients with refractory sarcomas, a p.

Botensilimab/Balstilimab Clinical Responses in Refractory Sarcomas Presented at ESMO 2024

LOS ANGELES, CA / ACCESSWIRE / September 12, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 23, 2023 and July 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 5, 2024.

Agenus Inc May Have Committed Securities Fraud And Investors Are Invited To Help The Schall Law Firm With A Lawsuit

NEW YORK, Sept. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”). Investors have until November 5, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

AGENUS ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Agenus Inc. and Encourages Investors to Contact the Firm

NEWTOWN, Pa. , Sept. 11, 2024 /PRNewswire/ -- Edelson Lechtzin LLP, a leading class action law firm, is investigating securities fraud claims on behalf of all investors of Agenus, Inc. ("Agenus") (NASDAQ: AGEN) between January 23, 2023, and July 17, 2024, inclusive (the "Class Period").

AGEN INVESTOR ALERT: Edelson Lechtzin LLP Urges Agenus, Inc. (NASDAQ: AGEN) Shareholders to Seek Legal Counsel About the Pending Securities Fraud Class Action

LOS ANGELES, CA / ACCESSWIRE / September 11, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 23, 2023 and July 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 5, 2024.

The Schall Law Firm Wants Shareholders To Reach Out About A Case Against Agenus Inc. For Securities Law Violations

NEW YORK, Sept. 10, 2024 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 5, 2024.

ROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Agenus Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – AGEN

SAN DIEGO, Sept. 10, 2024 (GLOBE NEWSWIRE) -- Robbins LLP informs investors that a shareholder filed a class action on behalf of all persons and entities who purchased or otherwise acquired Agenus Inc. (NASDAQ: AGEN) securities between January 23, 2023 and July 17, 2024.

Investor Notice: Robbins LLP Informs Stockholders of the Class Action Lawsuit Filed Against Agenus Inc.

LOS ANGELES, CA / ACCESSWIRE / September 10, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for for violations of 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. Investors who purchased the Company's securities between January 23, 2023 and July 17, 2024, inclusive (the "Class Period"), are encouraged to contact the firm before November 5, 2024.

Agenus Inc May Have Committed Securities Fraud And Affected Investors Should Join The Schall Law Firm In A Lawsuit

LOS ANGELES--(BUSINESS WIRE)--AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit with the Schall Law Firm.

AGEN Investors Have Opportunity to Lead Agenus Inc. Securities Fraud Lawsuit with the Schall Law Firm

NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, announces that a shareholder filed a class action on behalf of all purchasers of securities of Agenus Inc. (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024. Agenus describes itself as a “clinical-stage biotechnology company that discovers and develops immuno-oncology (“I-O”) products in the U.S. and internationally.” For more information, submit a form, email attorney Phillip Kim, or give us a call at 866-767.

Rosen Law Firm Urges Agenus Inc. (NASDAQ: AGEN) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Bernstein Liebhard LLP announces that a shareholder has filed a securities class action lawsuit on behalf of investors (the “Class”) who purchased or acquired the securities of Agenus Inc. (“Agenus” or the “Company”) (NASDAQ: AGEN) between January 23, 2023 and July 17, 2024, inclusive (the “Class Period”).

AGENUS INC. (NASDAQ: AGEN) INVESTOR ALERT: Investors With Large Losses in Agenus Inc. Should Contact Bernstein Liebhard LLP To Discuss Their Rights

ATLANTA, Sept. 09, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Agenus Inc. (“Agenus” or “the Company”) (NASDAQ: AGEN). The lawsuit alleges that Defendants made false and/or misleading statements and/or failed to disclose material information regarding the Company's business, operations, and prospects, including allegations that: (i) the combination therapy of botensilimab and balstilimab was less effective than Defendants had led investors to believe; and (ii) accordingly, botensilimab and balstilimab's clinical results, as well as their regulatory and commercial prospects, were overstated.

SHAREHOLDER ALERT: Class Action Lawsuit Filed on Behalf of Agenus Inc. (AGEN) Investors – Holzer & Holzer, LLC Encourages Investors With Significant Losses to Contact the Firm

LOS ANGELES, CA / ACCESSWIRE / September 9, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Has Launched An Inquiry Into Agenus Inc. For Potential Securities Law Violations And Stockholders Are Urged To Lend A Hand

NEW YORK, Sept. 09, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the District of Massachusetts on behalf of all persons or entities who purchased or otherwise acquired Agenus Inc. (NASDAQ: AGEN) securities between January 23, 2023 and July 17, 2024, inclusive (the “Class Period”). The lawsuit seeks to recover damages for the Company's investors under the federal securities laws.

Gainey McKenna & Egleston Announces A Class Action Lawsuit Has Been Filed Against Agenus, Inc. (AGEN)

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced that updated data from the clinical trial of botensilimab and balstilimab in refractory sarcomas will be featured in a mini oral presentation at the European Society for Medical Oncology (ESMO) Congress, taking place September 13-17, 2024, in Barcelona, Spain. The presentation will feature updated efficacy and safety data from the.

Botensilimab/Balstilimab Clinical Activity in Refractory Sarcomas to be Presented in Oral Session at ESMO 2024

LOS ANGELES, CA / ACCESSWIRE / September 7, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Agenus Inc Is Being Looked Into For Committing Securities Fraud And The Schall Law Firm Wants Investors To Reach Out

NEW YORK, NY / ACCESSWIRE / September 6, 2024 / Pomerantz LLP announces that a class action lawsuit has been filed against Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN) and certain officers. The class action, filed in the United States District Court for the District of Massachusetts, and docketed under 24-cv-12299, is on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Agenus securities between January 23, 2023 and July 17, 2024, both dates inclusive (the "Class Period"), seeking to recover damages caused by Defendants' violations of the federal securities laws and to pursue remedies under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and Rule 10b-5 promulgated thereunder, against the Company and certain of its top officials.

Pomerantz Law Firm Announces the Filing of a Class Action Against Agenus Inc. and Certain Officers - AGEN

LOS ANGELES, CA / ACCESSWIRE / September 6, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Stockholders With Losses In Agenus Inc. Are Invited To Join The Schall Law Firm's Investigation Into Possible Fraud

LOS ANGELES, CA / ACCESSWIRE / September 5, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

Agenus Inc May Have Committed Securities Related Impropriety And Investors Should Contact The Schall Law Firm About An Inquiry

LOS ANGELES, CA / ACCESSWIRE / September 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

The Schall Law Firm Wants Stakeholders To Partake In An Investigation Into Agenus Inc.'s Possible Securities Fraud

LOS ANGELES, CA / ACCESSWIRE / September 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Agenus Inc. ("Agenus" or "the Company") (NASDAQ:AGEN) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors.

News for Agenus Stock (AGEN)